Abstract
Background; We investigated the salivation-promoting effects of nizatidine in Sjögren's syndrome patients with xerostomia.
Methods; In a randomized crossover study using anetholtrithion as the control drug, changes in the salivary secretion with time and the adverse reactions to nizatidine were examined.
Results; Nizatidine produced significant increase of salivary secretion at 8 and 12 weeks as compared with the baseline (p = 0.0084, p = 0.0048). But the subjective symptom score showed no significant changes. The incidences of adverse drug reactions were much lower.
Conclusion; The results suggested that nizatidine is effective in the treatment of xerostomia in Sjögren's syndrome patients.
